Clinical meaning
Bile duct injury (BDI) is the most feared complication of cholecystectomy, occurring in 0.3-0.7% of laparoscopic procedures compared to 0.1-0.2% in open surgery. The Strasberg classification system categorizes BDI by anatomic severity: Type A involves bile leak from the cystic duct stump or minor hepatic duct (a duct of Luschka); Type B is occlusion of an aberrant right hepatic duct; Type C is transection of an aberrant duct without ligation; Type D is a lateral injury to an extrahepatic duct; and Type E encompasses injuries to the main hepatic duct (subdivided E1-E5 by the Bismuth classification based on level of stricture relative to the hepatic duct confluence). Type A injuries are the most common and generally manageable with percutaneous or endoscopic drainage plus biliary stenting. Type E injuries carry the worst prognosis and frequently require hepaticojejunostomy (Roux-en-Y reconstruction).
Postcholecystectomy syndrome (PCS) occurs in 10-40% of patients and encompasses a heterogeneous group of symptoms persisting or developing after cholecystectomy. Biliary causes include retained common bile duct (CBD) stones, bile duct stricture, cystic duct remnant syndrome, and sphincter of Oddi dysfunction (SOD). Non-biliary causes include peptic ulcer disease, IBS, chronic pancreatitis, and gastroesophageal reflux. SOD is classified by the Milwaukee classification into three types based on the presence of biliary pain, elevated liver enzymes, dilated CBD, and delayed drainage on hepatobiliary scintigraphy.
Bile acid malabsorption (BAM) occurs because the gallbladder normally concentrates bile acids during fasting and releases them postprandially. Without the gallbladder reservoir, bile acids enter the duodenum continuously in a dilute stream, and excess bile acids reaching the colon cause secretory diarrhea by stimulating chloride and water secretion. BAM affects up to 20% of postcholecystectomy patients and responds to bile acid sequestrant therapy (cholestyramine).